Skip to main content

Table 6 Percent of cells on day 21 following the therapy, normalized to the initial levels before the therapy. Values above 100 indicate the cell counts have increased above the initial levels

From: Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

Patient number

Breast cancer stage

CD8 + perforin + T cells

CD123+

CD11+

CD25 + CD127–

After the 1st round of chemotherapy

After the 3rd round of chemotherapy

After the 1st round of chemotherapy

After the 3rd round of chemotherapy

After the 1st round of chemotherapy

After the 3rd round of chemotherapy

After the 1st round of chemotherapy

After the 3rd round of chemotherapy

FAC chemotherapy + Placebo

 02–12a

IIIA

122.2

111.1

440.9

118.2

150.5

30.9

26.8

34.1

 02–07

IIIB

46.7

105.6

80.0

176.7

43.8

200.0

220.8

54.7

FAC chemotherapy + Panagen

 02–02

IIA

300.0

420.0

92.3

615.4

92.9

333.3

1.1

81.8

 02–10

IIA

178.6

178.6

543.8

37.5

666.7

83.3

120.0

62.0

 02–03

IIA

100.0

23.3

61.4

59.1

41.1

41.1

4.5

116.7

 02–11a

IIB

123.5

58.8

310.3

34.5

66.1

14.0

16.7

133.3

 02–15

IIIA

33.3

 

26.9

23.1

54.8

19.4

69.2

69.2

 02–05

IIIB

39.4

106.3

35.3

220.6

62.7

178.0

180.0

160.0

 02–14

IIIB

-

 

153.8

123.1

97.7

85.2

127.3

118.2

 02–01

IIIB

200.0

525.0

263.0

42.0

150.0

42.0

200.0

200.0

 02–08

IIIB

61.8

117.6

88.2

188.2

204.8

202.4

175.0

300.0

  1. Note: a – tamoxifen treatment. Patients who progressed or died are shown in boldface